Highlights MediciNova, Inc.

Equities

MNOV

US58468P2065

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-01 pm EDT			5-day change	1st Jan Change
1.29 ^USD	0.00%		-4.80%	-14.00%

Mar. 27	MediciNova, Inc. Receives a Notice of Allowance for a New Patent Covering MN-166 for the Treatment of Macular Injury in Japan	CI
Mar. 12	Medicinova Announces New Data and Results of Mn-166 in Chlorine Gas-Induced Acute Lung Injury Presented At the 63Rd Annual Meeting of the Society of Toxicology	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

MediciNova, Inc. Receives a Notice of Allowance for a New Patent Covering MN-166 for the Treatment of Macular Injury in Japan	Mar. 26	CI
Medicinova Announces New Data and Results of Mn-166 in Chlorine Gas-Induced Acute Lung Injury Presented At the 63Rd Annual Meeting of the Society of Toxicology	Mar. 12	CI
MediciNova, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 15	CI
MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 for the Treatment of Macular Injury in China	Jan. 17	CI
MediciNova, Inc. Announces Abstract Regarding MN-166 in Chlorine Gas-Induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology	Dec. 21	CI
MediciNova, Inc. Receives a Notice of Decision to Grant for a New Patent Covering MN-166 for the Treatment of Progressive MS in Europe	Dec. 06	CI
MediciNova, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
MediciNova Secures Patent Notice of Allowance in Canada for Amyotrophic Lateral Sclerosis Combination Treatment	23-10-11	MT
MediciNova, Inc. Receives a Notice of Allowance for a New Patent Covering the Combination of MN-166 and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis in Canada	23-10-10	CI
MediciNova, Inc. Announces Results of Studies Under BARDA Contract to Develop MN 166 as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury	23-09-27	CI
MediciNova Announces Abstract Regarding MN-166 in Glioblastoma Accepted for Presentation at the Annual Meeting of the Society for Neuro-Oncology	23-08-17	CI
MediciNova Says European Patent Office Issued Notice of Intention to Grant on Macular Injury Therapy Application	23-08-17	MT
MediciNova, Inc. Receives A Notice of Intention to Grant for A New Patent Covering MN-166 for the Treatment of Macular Injury in Europe	23-08-16	CI
Fed Minutes Anticipation Lifts Exchange-Traded Funds, Equity Futures Slightly Premarket Wednesday	23-08-16	MT
MediciNova Says European Patent Office Granted New Patent Covering Scleroderma, Systemic Sclerosis Treatment	23-08-16	MT
Medicinova Receives New Patent Covering MN-001 for the Treatment of Scleroderma and Systemic Sclerosis in Europe	23-08-15	CI
MediciNova, Inc. Receives New Patent Covering MN-001 for the Treatment of Scleroderma and Systemic Sclerosis in Europe	23-08-15	CI
MediciNova Says European Patent Office Issued Notice of Intention to Grant on NASH Treatments Application	23-08-15	MT
MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in Europe	23-08-14	CI
MediciNova, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights MediciNova, Inc.

Equities

MNOV

US58468P2065

Highlights

Filters